Grunow J E, Howard S
Department of Pediatrics, University of Oklahoma, Oklahoma City.
J Pediatr Gastroenterol Nutr. 1988 Jan-Feb;7(1):64-7. doi: 10.1097/00005176-198801000-00013.
As an intravenous injection is not used in our premedication of infants and children for small bowel biopsy, we investigated what effects oral metoclopramide might have on small bowel biopsy procedure time and fluoroscopy time. Eighteen infants and children were randomized to receive 0.2 mg/kg metoclopramide or placebo orally, 40-45 min before starting the procedure, and the procedure was monitored for the time required for the biopsy capsule to reach the pylorus, to cross into the proximal duodenum, and to reach the biopsy site. Corresponding fluoroscopy times were recorded as well. Mean total procedure time was less for those treated with metoclopramide, 43.7 +/- 11 min, than for controls, 86.5 +/- 15.5 min (p less than 0.005). Mean total fluoroscopy time was also less in treated patients (40.9 +/- 11.5 s versus control 84.4 +/- 17 s) (p less than 0.005). The effect of metoclopramide occurred in the interval for the biopsy capsule to cross the pylorus (15.1 +/- 2.7 min versus control 60.8 +/- 16.6 min) (p less than 0.005) and in fluoroscopy time required (15.1 +/- 1.9 s versus control 46 +/- 17 s) (p less than 0.005). Oral metoclopramide is effective in reducing procedure time for small bowel biopsy, and its predictable action facilitates reduction in fluoroscopy exposure.
由于在我们对婴幼儿进行小肠活检的术前用药中不使用静脉注射,我们研究了口服胃复安对小肠活检操作时间和透视时间可能有什么影响。18名婴幼儿被随机分为两组,在开始操作前40 - 45分钟口服0.2mg/kg胃复安或安慰剂,对活检胶囊到达幽门、进入十二指肠近端以及到达活检部位所需的时间进行监测。同时记录相应的透视时间。接受胃复安治疗的患者平均总操作时间为43.7±11分钟,短于对照组的86.5±15.5分钟(p<0.005)。治疗组患者的平均总透视时间也较短(40.9±11.5秒,对照组为84.4±17秒)(p<0.005)。胃复安的作用出现在活检胶囊穿过幽门的时间段(15.1±2.7分钟,对照组为60.8±16.6分钟)(p<0.005)以及所需的透视时间上(15.1±1.9秒,对照组为46±17秒)(p<0.005)。口服胃复安可有效缩短小肠活检的操作时间,其可预测的作用有助于减少透视暴露。